Mar 13, 2026 09:54AM
Feb 24, 2026 07:30PM
Oct 16, 2025 08:23PM
Oct 16, 2025 08:23PM
Mar 28, 2025 09:35PM
Mar 26, 2025 09:00PM
Jan 17, 2025 05:56AM Junshi Biosciences Announces Toripalimab’s Approval in Australia
Sep 24, 2024 11:29PM
Aug 30, 2024 11:56PM
Aug 12, 2024 09:30AM
Jul 26, 2024 10:46AM
Jul 17, 2024 11:38PM
Jun 25, 2024 07:43AM
Jun 18, 2024 03:32AM Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
Jun 11, 2024 10:06PM
Apr 24, 2024 10:11PM
Apr 7, 2024 08:46AM
Mar 29, 2024 12:24AM
Feb 1, 2024 10:40PM
Jan 17, 2024 11:05PM
Jan 9, 2024 10:15PM Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi
Dec 1, 2023 10:39PM
Oct 27, 2023 03:10PM
Oct 27, 2023 03:07PM
Aug 30, 2023 11:34PM
Jul 19, 2023 10:49PM
Jul 11, 2023 09:17PM
May 23, 2023 01:53AM Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer
May 7, 2023 10:07AM
Apr 27, 2023 08:05AM
Apr 27, 2023 04:36AM
Apr 20, 2023 04:01PM
Apr 11, 2023 11:47PM
Apr 11, 2023 11:34PM
Mar 31, 2023 04:00AM Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
Mar 30, 2023 08:28PM
Mar 28, 2023 11:39PM
Feb 27, 2023 11:50PM
Feb 20, 2023 10:53PM
Feb 15, 2023 09:25AM
Feb 15, 2023 08:25AM
Jan 30, 2023 08:24AM Junshi Biosciences Announces Approval for Marketing of VV116 in China
Jan 17, 2023 11:11PM
Jan 17, 2023 10:56PM
Dec 29, 2022 01:31AM
Dec 26, 2022 03:06AM
Dec 25, 2022 08:16AM
Dec 24, 2022 12:01AM
Dec 10, 2022 06:30PM Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
Nov 24, 2022 07:30AM

329,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All